Leustatin, Litak(cladribine)
Cladribine, Litak, Mavenclad (cladribine) is a small molecule pharmaceutical. Cladribine was first approved as Leustatin on 1993-02-26. It is used to treat b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hairy cell leukemia and multiple sclerosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cladribine, Mavenclad (discontinued: Cladribine, Leustatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cladribine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MAVENCLAD | EMD Serono | N-022561 RX | 2019-03-29 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cladribine | ANDA | 2025-01-23 |
| mavenclad | New Drug Application | 2024-05-21 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
HCPCS
Code | Description |
|---|---|
| J9065 | Injection, cladribine, per 1 mg |
Clinical
Clinical Trials
207 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | 3 | 1 | 5 |
| Sclerosis | D012598 | — | — | — | — | 1 | 2 | 1 | 4 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | 1 | — | 2 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cladribine |
| INN | cladribine |
| Description | Cladribine is 2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia. It has a role as an antineoplastic agent and an immunosuppressive agent. It is a purine 2'-deoxyribonucleoside and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | ribofuranil derivatives (pyrazofurin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1 |
Identifiers
| PDB | — |
| CAS-ID | 4291-63-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1619 |
| ChEBI ID | 567361 |
| PubChem CID | 20279 |
| DrugBank | DB00242 |
| UNII ID | 47M74X9YT5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,081 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cladribine, Mavenclad
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,158 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use